Morgan Stanley analyst Terence Flynn raised the firm’s price target on BioNTech (BNTX) to $126 from $125 and keeps an Overweight rating on the shares. The firm adjusted models among its biopharma coverage for IQVIA trends as well as intra-quarter updates ahead of Q1 earnings reporting from the group.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BNTX:
- BioNTech Earnings Call: Cash-Rich Pivot Beyond COVID
- BioNTech Calls Virtual 2026 AGM, Seeks Larger Supervisory Board to Back Oncology Push
- BioNTech price target lowered to $130 from $140 at H.C. Wainwright
- BioNTech’s Mpox Vaccine Study Reaches Completion: What Investors Should Watch Next
- BioNTech Showcases Late-Stage Lung Cancer Portfolio at ELCC 2026 With Promising Clinical Data